Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial

被引：0
|
作者：
Kris, M. G. [1 ]
Riely, G. J. [1 ]
Azzoli, C. G. [1 ]
Heelan, R. T. [1 ]
Krug, L. M. [1 ]
Pao, W. [1 ]
Milton, D. T. [1 ]
Moore, E. [1 ]
Rizvi, N. A. [1 ]
Miller, V. A. [1 ]
机构：
[1] Memor Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7575
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Milton, DT
    Kris, MG
    Azzoli, CG
    Gomez, JE
    Heelan, R
    Krug, LM
    Pao, W
    Pizzo, B
    Rizvi, NA
    Miller, VA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 646S - 646S
  • [2] PHASE I TRIAL OF RAD001 (EVEROLIMUS) IN COMBINATION WITH RADIOTHERAPY IN NON-SMALL CELL LUNG CANCER
    Deutsch, E.
    Lepechoux, C.
    Pignon, J. P.
    Tao, Y. T.
    Rivera, S.
    Bourgier, B. C.
    Angokai, M.
    Bahleda, R.
    Slimane, K.
    Angevin, E.
    Besse, B. B.
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2013, 24 : 9 - 9
  • [3] Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)
    White, Dorothy A.
    Schwartz, Lawrence H.
    Dimitrijevic, Sasa
    Di Scala, Lilla
    Hayes, Wendy
    Gross, Stefan H.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1357 - 1363
  • [4] Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
    Price, Katharine A.
    Azzoli, Christopher G.
    Krug, Lee M.
    Pietanza, Maria C.
    Rizvi, Naiyer A.
    Pao, William
    Kris, Mark G.
    Riely, Gregory J.
    Heelan, Robert T.
    Arcila, Maria E.
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1623 - 1629
  • [5] Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
    Tarhini, Ahmad
    Kotsakis, Athanasios
    Gooding, William
    Shuai, Yongli
    Petro, Daniel
    Friedland, David
    Belani, Chandra P.
    Dacic, Sanja
    Argiris, Athanassios
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5900 - 5907
  • [6] Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC)
    Kotsakis, A. P.
    Tarhini, A.
    Petro, D.
    Flaugh, R.
    Vallabhaneni, G.
    Belani, C. P.
    Friedland, D.
    Argiris, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC)
    Owonikoko, T. K.
    Stoller, R. G.
    Petro, D.
    Flaugh, R.
    Hershberger, P. A.
    Belani, C. P.
    Argiris, A. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non-small cell lung cancer
    Johnson, Bruce E.
    Jackman, David
    Janne, Pasi A.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4628S - 4631S
  • [9] Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC)
    Kotsakis, Athanasios
    Tarhini, Ahmad
    Petro, Daniel
    Flaugh, Rick
    Vallabhaneni, Geetha
    Belani, Chandra
    Friedland, David
    Argiris, Athanassios
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S464 - S464
  • [10] Chemical genomics of RAD001 in Non-Small Cell Lung Cancer
    Seidel, Daniela
    Ansen, Sascha
    Thomas, Roman
    Wolf, Juergen
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S800 - S800
12345